Risk factors for the acquisition of OXA-48-producing Enterobacteriaceae in a hospital outbreak setting: A matched case-control study

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2273-2279

  Dautzenberg, M J D ^a,b   Ossewaarde, J M ^b   de Greeff, S C ^c   Troelstra, A ^a   Bonten, M J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFAZOLIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; METRONIDAZOLE; QUINOLONE DERIVATIVE; BETA LACTAMASE;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; COMORBIDITY; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EPIDEMIC; FEMALE; GENDER; HOSPITAL ADMISSION; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OXA 48 PRODUCING ENTEROBACTERIACEAE; RETROSPECTIVE STUDY; RISK FACTOR; WARD; CASE CONTROL STUDY; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NETHERLANDS; SECRETION (PROCESS); TRANSMISSION;

AGED; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS INFECTION; DISEASE OUTBREAKS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK FACTORS;

EID: 84982239162     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw119     Document Type: Article

References (34)

1. Poirel L, Hé ritier C, Tolün V, Nordmann P. Emergence of oxacillinasemediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
2. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 60-7.
3. Nordmann P, Gniadkowski M, Giske CG et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012; 18: 432-8.
4. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20: 821-30.
5. Poirel L, Ros A, Carrër A et al. Cross-border transmission of OXA-48- producing Enterobacter cloacae from Morocco to France. J Antimicrob Chemother 2011; 66: 1181-2.
6. Gasink LB, Edelstein PH, Lautenbach E et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009; 30: 1180-5.
7. Papadimitriou-Olivgeris M, Marangos M, Fligou F et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 2012; 67: 2976-81.
8. Swaminathan M, Sharma S, Poliansky Blash S et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013; 34: 809-17.
9. Marchaim D, Navon-Venezia S, Schwaber MJ et al. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52: 1413-8.
10. Patel N, Harrington S, Dihmess A et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 1600-8.
11. Gagliotti C, Giordani S, Ciccarese V et al. Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study. Am J Infect Control 2014; 42: 1006-8.
12. Patel G, Huprikar S, Factor SH et al. Outcomes of carbapenemresistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
13. Dautzenberg MJ, Ossewaarde JM, de Kraker ME et al. Successful control of a hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in the Netherlands, 2009 to 2011. Euro Surveill 2014; 19: pii=20723.
14. Bonten MJ. Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria. Crit Care 2012; 16: 142.
15. D'Agata EMC. Methodologic issues of case-control studies: a review of established and newly recognized limitations. Infect Control Hosp Epidemiol 2005; 26: 338-41.
16. McGregor JC, Perencevich EN, Furuno JP et al. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006; 59: 1266-73.
17. Breslow NE, Day NE. Statistical methods in cancer research. Volume I- The analysis of case-control studies. IARC Sci Publ 1980; 32: 5-338.
18. Heinze G, Puhr R. Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets. Stat Med 2010; 29: 770-7.
19. Balkan II, Aygün G, Aydin S et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 2014; 26: 51-6.
20. Thomas CP, Moore LSP, Elamin N et al. Early (2008-2010) hospital outbreak of Klebsiella pneumoniae producing OXA-48 carbapenemase in the UK. Int. J Antimicrob Agents 2013; 42: 531-6.
21. Kola A, Piening B, Pape U-F et al. An outbreak of carbapenem-resistant OXA-48-producing Klebsiella pneumonia associated to duodenoscopy. Antimicrob Resist Infect Control 2015; 4: 8.
22. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 2013; 19: E72-9.
23. Schechner V, Temkin E, Harbarth S et al. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 2013; 26: 289-307.
24. Harris AD, Karchmer TB, Carmeli Y et al. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32: 1055-61.
25. Kaye KS, Harris AD, Samore M et al. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26: 346-51.
26. Harris AD, Carmeli Y, Samore MH et al. Impactof severityof illnessbiasand control group misclassification bias in case-control studies of antimicrobialresistant organisms. Infect Control Hosp Epidemiol 2005; 26: 342-5.
27. Van der Zee A, Roorda L, Bosman G et al. Multi-centre evaluation of real-time multiplex PCR for detection of carbapenemase genes OXA-48, VIM, IMP, NDM and KPC. BMC Infect Dis 2014; 14: 27.
28. Pano-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C et al. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 2012; 68: 89-96.
29. Giani T, Conte V, Mandalà S et al. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. J Clin Microbiol 2014; 52: 2702-5.
30. Lautenbach E, Strom BL, Bilker WB et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33: 1288-94.
31. Lautenbach E, Metlay JP, Weiner MG et al. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect Control Hosp Epidemiol 2009; 30: 18-24.
32. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-33.
33. Barguigua A, Zerouali K, Katfy K et al. Occurrence of OXA-48 and NDM-1 carbapenemase-producing Klebsiella pneumoniae in a Moroccan university hospital in Casablanca, Morocco. Infect Genet Evol 2015; 31: 142-8.
34. OXA-48 carbapenemase in clinical isolates of Klebsiella pneumoniae in Spain. Enferm Infecc Microbiol Clin 2014; 32: 441-2.